Amplifon stock in focus after Q3 margin expansion

Amplifon reported stronger profitability in the third quarter on October 29, 2026, while maintaining its full-year targets. In its third-quarter results release, the hearing-care group said organic growth reached 3.6 percent against the highest comparison base of the year.

Amplifon stock traded at 12.27 euros on Lang & Schwarz at 10:44 CET on Thursday, November 5, 2026. Investors can follow the real-time quote of Amplifon stock.

Margins Outpace Revenue Growth

For the first nine months, revenue reached 1,760.8 million euros, an increase of 0.9 percent at constant exchange rates. Organic growth contributed 3.5 percent, while acquisitions added 0.7 percent. The Fit4Growth program reduced revenue by 3.3 percent through network optimization and the divestment or termination of dilutive businesses.

Adjusted EBITDA rose 4.5 percent to 412.8 million euros in the nine-month period, with the margin increasing 80 basis points to 23.4 percent. Adjusted EBIT climbed 11.5 percent to 222.0 million euros, lifting its margin by 120 basis points to 12.6 percent. Adjusted net profit advanced 16.9 percent to 128.2 million euros.

The improvement accelerated in the third quarter. Adjusted EBITDA increased 7.0 percent and its margin widened by 90 basis points. Adjusted EBIT grew 21.9 percent, with the margin expanding 150 basis points to 9.1 percent, while adjusted net profit rose 38.7 percent. Amplifon defines these adjusted figures as excluding unusual, infrequent or unrelated items outside the normal course of business.

Cash Flow And Deal Preparation

Adjusted free cash flow increased 138.6 percent to 79.1 million euros in the first nine months after capital expenditure of 64.3 million euros. Pro forma net financial debt stood at 1,052.8 million euros at September 30, 2026, excluding proceeds from the equity raise intended to help finance the GN Hearing acquisition. Financial leverage improved to 1.85 times.

Chief Executive Enrico Vita said the quarter confirmed a solid improvement in performance, supported by operating leverage and Fit4Growth. He added that planning for the GN Hearing integration was progressing according to schedule, with the company aiming to be fully prepared when the acquisition closes.

Amplifon confirmed its 2026 outlook for organic growth above 3 percent and an increase in the adjusted EBITDA margin in the region of 100 basis points. The company also pointed to market-share gains in key markets and continued operating leverage as support for the plan.

Execution Remains The Next Test

The stronger margins improve the operating picture, but the unchanged guidance leaves execution in the final quarter as the next investor focus. The GN Hearing transaction adds a strategic growth opportunity while making regulatory clearance and integration readiness important milestones for the investment case.

European equities and Italian shares remain part of the wider FTSE MIB market environment.

More company-specific developments are available in more news and analyses on Amplifon stock.